Compare Abbott India with Unichem Lab - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs UNICHEM LAB - Comparison Results

ABBOTT INDIA     Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA UNICHEM LAB ABBOTT INDIA/
UNICHEM LAB
 
P/E (TTM) x 49.0 -44.1 - View Chart
P/BV x 15.8 1.1 1,461.6% View Chart
Dividend Yield % 0.4 1.3 34.0%  

Financials

 ABBOTT INDIA   UNICHEM LAB
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-19
UNICHEM LAB
Mar-19
ABBOTT INDIA/
UNICHEM LAB
5-Yr Chart
Click to enlarge
High Rs8,834292 3,025.4%   
Low Rs5,458182 2,998.6%   
Sales per share (Unadj.) Rs1,731.1167.7 1,032.5%  
Earnings per share (Unadj.) Rs211.9-3.6 -5,836.9%  
Cash flow per share (Unadj.) Rs219.95.9 3,700.7%  
Dividends per share (Unadj.) Rs65.004.00 1,625.0%  
Dividend yield (eoy) %0.91.7 53.9%  
Book value per share (Unadj.) Rs945.2372.3 253.9%  
Shares outstanding (eoy) m21.2570.38 30.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.11.4 292.0%   
Avg P/E ratio x33.7-65.3 -51.7%  
P/CF ratio (eoy) x32.539.9 81.5%  
Price / Book Value ratio x7.60.6 1,187.4%  
Dividend payout %30.7-110.2 -27.8%   
Avg Mkt Cap Rs m151,84816,680 910.4%   
No. of employees `0003.52.6 133.9%   
Total wages/salary Rs m4,3562,393 182.0%   
Avg. sales/employee Rs Th10,555.54,535.2 232.7%   
Avg. wages/employee Rs Th1,249.9919.8 135.9%   
Avg. net profit/employee Rs Th1,292.2-98.2 -1,315.8%   
INCOME DATA
Net Sales Rs m36,78611,801 311.7%  
Other income Rs m1,133984 115.1%   
Total revenues Rs m37,91912,785 296.6%   
Gross profit Rs m6,047-835 -724.3%  
Depreciation Rs m169674 25.1%   
Interest Rs m2375 29.9%   
Profit before tax Rs m6,989-600 -1,165.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,485-343 -723.6%   
Profit after tax Rs m4,503-256 -1,762.3%  
Gross profit margin %16.4-7.1 -232.4%  
Effective tax rate %35.657.3 62.1%   
Net profit margin %12.2-2.2 -565.3%  
BALANCE SHEET DATA
Current assets Rs m27,61020,384 135.4%   
Current liabilities Rs m8,5695,029 170.4%   
Net working cap to sales %51.8130.1 39.8%  
Current ratio x3.24.1 79.5%  
Inventory Days Days60105 57.5%  
Debtors Days Days27135 20.3%  
Net fixed assets Rs m1,0579,023 11.7%   
Share capital Rs m213141 150.9%   
"Free" reserves Rs m19,87326,058 76.3%   
Net worth Rs m20,08626,199 76.7%   
Long term debt Rs m00-   
Total assets Rs m29,40931,496 93.4%  
Interest coverage x311.6-7.0 -4,467.6%   
Debt to equity ratio x00-  
Sales to assets ratio x1.30.4 333.9%   
Return on assets %15.4-0.6 -2,687.8%  
Return on equity %22.4-1.0 -2,298.7%  
Return on capital %34.9-2.0 -1,745.9%  
Exports to sales %069.4 0.0%   
Imports to sales %00-   
Exports (fob) Rs mNA8,188 0.0%   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3698,188 4.5%   
Fx outflow Rs m4,918596 825.2%   
Net fx Rs m-4,5497,592 -59.9%   
CASH FLOW
From Operations Rs m4,991-3,278 -152.3%  
From Investments Rs m-2,570-2,860 89.9%  
From Financial Activity Rs m-1,428-24 5,900.8%  
Net Cashflow Rs m993-4,690 -21.2%  

Share Holding

Indian Promoters % 0.0 50.1 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 15.1 52.3%  
FIIs % 0.1 3.0 3.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 31.7 53.9%  
Shareholders   18,270 20,176 90.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   ORCHID PHARMA  CIPLA  ASTRAZENECA PHARMA  AUROBINDO PHARMA  STERLING BIOTECH  

Compare ABBOTT INDIA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Zooms 661 Points, Nifty Ends Above 14,500; M&M and Bajaj Finserv Top Gainers(Closing)

Indian share markets witnessed most of the buying interest during closing hours today and ended on a strong note.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (3QFY21); Net Profit Down 5.1% (Quarterly Result Update)

Feb 11, 2021 | Updated on Feb 11, 2021

For the quarter ended December 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (down 5.1% YoY). Sales on the other hand came in at Rs 11 bn (up 1.6% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY21); Net Profit Up 54.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (4QFY20); Net Profit Down 2.0% (Quarterly Result Update)

Jun 9, 2020 | Updated on Jun 9, 2020

For the quarter ended March 2020, ABBOTT INDIA has posted a net profit of Rs 1 bn (down 2.0% YoY). Sales on the other hand came in at Rs 10 bn (up 6.1% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (3QFY20); Net Profit Up 59.5% (Quarterly Result Update)

Feb 11, 2020 | Updated on Feb 11, 2020

For the quarter ended December 2019, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 59.5% YoY). Sales on the other hand came in at Rs 11 bn (up 13.8% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY20); Net Profit Up 41.9% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 41.9% YoY). Sales on the other hand came in at Rs 10 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

If the Market Falls, I Will Do This...(Fast Profits Daily)

Apr 1, 2021

What should you do if the market falls? In this video, I'll tell you what I will do.

The Indian Real Estate Party Has Just Begun(Profit Hunter)

Apr 1, 2021

A favourable demand supply scenario makes a strong case for real estate prices.

The Dilemma of Investing in Bharti Airtel(Views On News)

Apr 1, 2021

Rahul Shah on whether Bharti Airtel will emerge as the next big thing in the Indian stock market

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Apr 13, 2021 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 5-YR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS